

HOSTED BY



ELSEVIER

Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Medicine

journal homepage: <http://ees.elsevier.com/apjtm>Original research <http://dx.doi.org/10.1016/j.apjtm.2016.05.018>

Evaluation of hypoxia inducible factor targeting pharmacological drugs as antileishmanial agents

Marina Dal'Bó Pelegrini, Juliana Biar Pereira, Solange dos Santos Costa, Myriam Janeth Salazar Terreros, Adriana Degrossoli, Selma Giorgio*

Department of Animal Biology, Biology Institute, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil

ARTICLE INFO

Article history:

Received 15 Apr 2016
 Received in revised form 16 May 2016
 Accepted 23 May 2016
 Available online 31 May 2016

Keywords:

Leishmaniosis
 Hypoxia inducible factor
 Resveratrol
 Echinomycin
 CdCl₂
 Mimosine

ABSTRACT

Objective: To evaluate whether hypoxia inducible factor (HIF-1 α) targeting pharmacological drugs, echinomycin, resveratrol and CdCl₂ which inhibit HIF-1 α stimulation, and mimosine, which enhances the stability of HIF-1 α present antileishmanial properties.

Methods: The leishmanicidal effect of drugs was evaluated in mouse macrophages and Balb/c mouse model for cutaneous leishmaniasis.

Results: Resveratrol and CdCl₂ reduced the parasite load [IC₅₀, (27.3 \pm 2.25) μ M and (24.8 \pm 0.95) μ M, respectively]. The IC₅₀ value of echinomycin was (22.7 \pm 7.36) nM and mimosine did not alter the parasite load in primary macrophages. The macrophage viability IC₅₀ values for resveratrol, echinomycin and CdCl₂ and mimosine were >40 μ M, >100 nM, >200 μ M and >2000 μ M, respectively. *In vivo* no differences between cutaneous lesions from control, resveratrol- and echinomycin-treated Balb/c mice were detected.

Conclusions: Resveratrol, echinomycin and CdCl₂ reduce parasite survival *in vitro*. The HIF-1 α targeting pharmacological drugs require further study to more fully determine their anti-*Leishmania* potential and their role in therapeutic strategies.

1. Introduction

Leishmanioses are diseases caused by intracellular *Leishmania* parasites of macrophages [1] and they are endemic in more than 90 countries [2]. *Leishmania amazonensis* (*L. amazonensis*) is transmitted mainly in the Amazon region and causes localized and diffuse cutaneous lesions and mucosal infection [3]. Leishmanioses are neglected diseases, there is no vaccine, current therapies fail to eradicate parasites from infected tissues and present side effects, while resistance to classical chemotherapy has become a clinical threat [2,4].

Recently our group and others have shown that mice with cutaneous leishmaniasis present hypoxic areas in damaged and infected tissues [5–7] and that *Leishmania*-infected macrophages

from lesions and infected macrophage cultures accumulate hypoxia inducible factor (HIF-1 α) [8–11]. HIF is a heterodimeric transcription factor consisting of HIF-1 α and HIF-1 β [12]. Under normoxia, HIF-1 α is hydroxylated on proline residues and degraded by the ubiquitin proteasome pathway while under hypoxia, hydroxylation is inhibited and heterodimerization, nuclear translocation and transcription of HIF-dependent genes such as erythropoietin, vascular endothelial growth factor and transferrin occur [12–14]. HIF-1 α overexpression is observed in a wide array of tumor cells that reprogram the metabolism for the induction of glycolytic enzymes [14]. Thus HIF-1 α is originally identified as a master regulator of the adaptive response to diminished oxygen supply and accumulates in ischemic tissues and various types of cancer and their metastases; HIF-1 α overexpression may trigger cell invasion and is associated with treatment failure [15,16]. The current understanding that HIF-1 α can be expressed during infection with bacteria, such as *Chlamydia* [17] viruses, such as Epstein Barr [18] and protozoa, such as *Leishmania* and *Theileria* [8,9,19] via oxygen-dependent and oxygen-independent pathways reveals its additional role as a transcriptional regulator of inflammation and infection [20].

Experimental therapeutics involving the pharmacological modulation of HIF-1 α has become a promising novel strategy;

*Corresponding author: Selma Giorgio, Department of Animal Biology, Biology Institute, Universidade Estadual de Campinas, Rua Monteiro Lobato, 13083-862, Campinas, São Paulo, Brazil.

Tel: +55 19 35216287;

Fax: +55 19 35216374

E-mails: sgiorgio@unicamp.br, selmagiorgio@gmail.com

Peer review under responsibility of Hainan Medical College.

Foundation project: This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico (NO. 2009/10771-9) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (NO. 301052/2009-3), Brazil.

small-molecule inhibitors of the HIF-1 α pathway identified through cell-based screening [15,16,21] and tests for various carcinogenesis and ischemic disease models have been reported in recent years [22–26].

Since sustained efforts are required to enrich new anti-leishmanial drug discovery, we aimed to evaluate whether echinomycin, a compound that inhibits the DNA binding activity of HIF-1 α [27], resveratrol which inhibits HIF-1 α through multiples mechanisms, including HIF protein degradation via the proteasome pathway [28] cadmium (CdCl₂), which is a heavy metal that triggers proteasome-dependent degradation of HIF-1 α [29], and mimosine, a hydroxylase inhibitor agonist that stabilizes HIF-1 α [30] present antileishmanial properties.

2. Material and methods

2.1. Reagents

Echinomycin, C₅₁H₆₄N₁₂O₁₂S₂, was purchased from Alexis Biochemicals (San Diego, CA, USA), L-mimosine, C₈H₁₀N₂O₄, was purchased from Enzo Life Sciences (Lausen, Switzerland), resveratrol, C₁₄H₁₂O₃, and cadmium chloride, CdCl₂, were purchased from Sigma–Aldrich (St. Louis, MO, USA), and meglumine antimoniate (glucantime) was purchased from Sanofi-Aventis (São Paulo, Brazil). Each of these compounds was dissolved in phosphate-buffered saline (PBS) or RPMI medium, resveratrol was dissolved in RPMI medium using small amounts (<0.01%) of dimethyl sulfoxide (DMSO) as required. Unless otherwise stated, all other reagents were obtained from Sigma–Aldrich.

2.2. Cell culture and parasites

Peritoneal mouse macrophages were obtained from normal BALB/c mice by peritoneal lavage, as previously described [31]. The cells were cultured in RPMI medium supplemented with 100 U/mL penicillin, 100 μ g/mL streptomycin and 10% fetal calf serum (Cultilab, Campinas, SP, Brazil) at 37 °C in 5% CO₂, 5% O₂ and balanced N₂. *L. amazonensis* (MHOM/BR/73/M2269) amastigotes were isolated from active skin lesions of BALB/c mice [32].

2.3. Assessment of the effect of drugs on *L. amazonensis* infected macrophages

Macrophages (5 \times 10⁵ cells/well) cultured in 24-well cell culture plates containing 13 mm diameter glass coverslips were exposed to *L. amazonensis* at a parasite/macrophage ratio of 3:1 for 2 h. Following exposure, the cultures were washed to remove extracellular parasites and then incubated in the presence of the drugs for 48 h. To evaluate the parasite load (number of amastigotes per macrophage), cells on coverslips were stained with Giemsa. The intracellular amastigotes, which are located exclusively in parasitophorous vacuoles, and 200 cells were examined microscopically at 1000 magnification [31]. All tests were performed in triplicate. The reduction in parasite load induced by the compounds was calculated as a percentage of the control (assuming 100% parasite load of untreated macrophages). The IC₅₀ describes the drug concentration that inhibits 50% of parasite load and was calculated using a curve fitting program (GraphPad Prism 6

software). Cellular viability was assessed by counting the adherent cells in 20 random fields of infected and uninfected macrophage cultures [33]. The IC₅₀ describes the drug concentration that inhibits 50% macrophage viability and, was calculated using a curve fitting program (GraphPad Prism 6 software).

2.4. Assessment of the effect of drugs on *L. amazonensis* infected mice

The Ethics Committee for Animal Research of the Institute of Biology of the State University of Campinas approved the experimental protocols. Six-week-old female BALB/c mice were subcutaneously inoculated in the right hind footpad with 10⁵ amastigotes. For each group of mice, 3 per group were administered the same vehicles (PBS and DMSO) without the compounds, resveratrol 15 mg/kg/day, echinomycin 0.13 mg/kg/day or glucantime 100 mg/kg/day [33–36] injected intraperitoneally for 20 d, 26 d after parasite inoculation. The course of infection was monitored by measuring the increase in footpad thickness with a dial caliper, compared with the contra lateral uninfected footpad [33]. This study was approved by the Ethics Committee of Universidade Estadual de Campinas (process numbers: 1742-1 and 2715-1).

2.5. Immunoblot analyses

The macrophages were scraped from the culture flasks and rinsed twice with PBS. Lysis buffer (62.5 mM Tris–HCl, pH 6.8, 69 mM SDS, 10% glycerol, 2% 2-mercaptoethanol, 34 mM ethylenediaminetetraacetic acid, 2 μ g/mL pepstatin and 1 mM phenylmethylsulfonyl fluoride) (Amersham Pharmacia Biotech, Piscataway, NJ, USA) was added to the cell pellets. Proteins were denatured at 95 °C for 3 min, electrophoresed on a 10% SDS-PAGE (poly-acrylamide) gel system (Thermo EC, USA) and transferred to nitrocellulose membranes (Amersham Pharmacia Biotech). After blotting, membranes were probed with rabbit polyclonal anti-HIF-1 α antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA and Sigma–Aldrich) and secondary antibody peroxidase-conjugated goat anti-rabbit IgG (Amersham, Poole, UK and Sigma–Aldrich); development was performed with 3,3'-diaminobenzidine. Immunoreaction images were scanned and the densitometric value of each band was determined using Image Master Total Lab version 1 software (Amersham Pharmacia Biotech).

2.6. Immunofluorescence analyses

Cells attached to the slide-chambers were fixed for 10 min with 4% paraformaldehyde and washed 3 times in PBS. The cells were permeabilized with 1% Tween 20 and then washed twice in PBS. Nonspecific binding sites were blocked with 3% BSA (Amresco, Solon, OH, USA) for 30 min. The macrophages were then incubated with mouse anti-*L. amazonensis* serum or anti-HIF-1 α antibody (Santa Cruz Biotechnology) overnight at 4 °C in a wet room. The cells were washed 4 times in PBS + 0.1% Tween 20 and incubated with FITC-conjugated goat anti-mouse secondary antibody or FITC-conjugated goat anti-rabbit secondary antibody for 1 h in a wet room at room temperature. The cells were washed four times in PBS + 0.1%

Tween 20 and mounted with DAPI-containing DABCO mounting media. The cells were visualized under a Nikon Eclipse 50i fluorescence microscope (Nikon, Melville, NY, USA). All images were captured and analyzed with a digital camera (Nikon DXM1200-F) and imaging software (ACT-1, Nikon).

2.7. Statistical analyses

All the experiments were repeated at least three times for *in vitro* assays and twice for *in vivo* assays. Statistical significance between the control and experimental groups were determined by the Student *t* test and the resulting data are expressed as the mean \pm SD.

3. Results

3.1. Expression of HIF-1 α in *Leishmania*-infected macrophages

Leishmania is an intracellular parasite that interferes with HIF-1 α expression *in vitro* and *in vivo* [9]. The immunofluorescence analyses confirmed that under the chosen experimental conditions intracellular amastigotes were established inside macrophages with (8.9 ± 3.2) parasites per infected cell (Figure 1A–B). The intensity and pattern of HIF-1 α immunostaining were similar between macrophage cultures in normoxia (21% O₂) and hypoxia (2% O₂) (Figure 1C–D), confirming that *Leishmania* activates HIF-1 α in macrophages [8,9]. HIF-1 α was expressed in *L. amazonensis* infected macrophages, as shown in the western blots, and was reduced following treatment with resveratrol, echinomycin and CdCl₂ (Figure 1E).

3.2. Effect of HIF-1 α targeting pharmacological drugs on viability of macrophages

The dose range of the pharmacological drugs used in the antileishmanial assays were chosen based on macrophage viability data for each compound; the IC₅₀ values obtained for resveratrol, echinomycin, CdCl₂, and mimosine were >40 μ M, >100 nM, >200 μ M, and >2000 μ M, respectively (Table 1); these results corroborate previous findings [9,34,37–39].

3.3. Effect of HIF-1 α targeting pharmacological drugs on *Leishmania* within macrophages

Next, the compounds were tested in antileishmanial assays. The IC₅₀ values of each drug are listed in Table 1. Resveratrol, CdCl₂ and echinomycin reduced the parasite load after 48 h of treatment [IC₅₀ (27.30 ± 2.25) μ M, (24.80 ± 0.95) μ M and (22.70 ± 7.36) nM, respectively]. Mimosine did not inhibit significantly the parasite load in *L. amazonensis* infected macrophages under the conditions tested (IC₅₀ > 80 μ M) (Table 1). Similar results were obtained

Table 1

In vitro antileishmanial and cytotoxicity of HIF-1 α targeting drugs.

Drugs	IC ₅₀	
	Intracellular amastigotes ^a	Macrophages ^b
Resveratrol	27.3 \pm 2.25 μ M	>40 μ M
CdCl ₂	24.8 \pm 0.95 μ M	>200 μ M
Echinomycin	22.7 \pm 7.36 nM	>100 nM
Mimosine	>80 μ M	>2000 μ M

^a Drug concentration that inhibit 50% of the parasite load (number of amastigotes per macrophage) at 48 h incubation time. ^b Drug concentration that inhibit 50% of the macrophage viability at 48 h incubation time.




Figure 1. HIF-1 α expression in *L. amazonensis* infected macrophages.

Florescent images of infected macrophages under normoxia labeled with anti-*L. amazonensis* serum (green) and nuclei labeled with DAPI (blue) (A); infected macrophages under hypoxia labeled with anti-*L. amazonensis* serum (green) and nuclei labeled with DAPI (blue) (B); or labeled with anti-HIF-1 α antibody (DAPI image, right side) (C); or labeled with anti-HIF-1 α antibody (DAPI image, right side) (D). Western blots (E) of extracts from infected macrophages nontreated (1) or treated with resveratrol 50 μ M; (2) echinomycin 10 nM; (3) CdCl₂ 25 μ M; (4) or mimosine 50 mM for 24 h.

using macrophage cell lines and primary human macrophages; the exception was *L. amazonensis* infected J774 macrophage cultures, which reduced the parasite load after mimosine treatment: IC₅₀ (56.00 ± 1.51) μM. The IC₅₀ value of a reference anti-*Leishmania* drug, amphotericin B was (0.040 ± 0.002) μM but a complete reduction of infection was not obtained [33].

3.4. Effect of resveratrol and echinomycin on *Leishmania*-infected mice

Since resveratrol and echinomycin have been tested in various animal models of cancer and other diseases [22,27,28,34], both compounds were evaluated in mice. Observation of individual footpad sizes of *L. amazonensis* infected Balb/c mice over time detected no significant differences between PBS/DMSO, resveratrol and echinomycin treatments; lesion in individual mouse progressively increased in size (Figure 2). In this experiment, three of the five (60%) echinomycin-treated mice died prematurely. No mortality was observed in PBS/DMSO- and resveratrol-treated mice; similar results were obtained in another independent experiment. Glucantime, which is used in the clinical treatment of leishmaniasis, prevented lesions (Figure 2) and ulcerations developed slowly, although a complete cure was not obtained.




Figure 2. Effects of HIF-1 α target drugs on *L. amazonensis* infection. Balb/c mice (3 per group) were treated intraperitoneally with PBS/DMSO (■, ▲, ●), glucantime (100 mg/kg/day) (□, △, ○), resveratrol (15 mg/kg/day) (*, -, +) or echinomycin 0.13 mg/kg/day (rhombuses) for 20 d, 26 d after parasite inoculation with 10⁵ amastigotes in the footpad. Lesion size is expressed as the difference in size between the infected and the contra lateral uninfected footpads.

4. Discussion

The modulation of HIF-1 α has been an interesting chemotherapy approach for many diseases and drugs that achieve this could be repositioned as infectious disease therapeutics [20]. Recently we showed that HIF-1 α is activated during *L. amazonensis* infection [5,7–9]. The picture emerging from these studies is that HIF-1 α induction and the target genes constitute part of an adaptation mechanism resulting from *Leishmania* infection and that this could permit the macrophage to attenuate damage, maintain integrity and survive the infection [9], since HIF-1 α transcriptional

regulation can support microbicidal and inflammatory phenotypes [20,24]. Reports on the anti-microorganism properties of HIF-1 α modulating drugs are scarce.

The addition of CdCl₂ to *L. amazonensis* infected macrophage cultures significantly reduced parasite survival, confirming our previous data [9]. Cadmium is a heavy metal that triggers proteasome-dependent degradation of HIF-1 α protein, depressing its activity as a hypoxia mimic; CdCl₂ was used only as an *in vitro* control since it is classified as a human carcinogen [40].

Our results also indicated that resveratrol reduced parasite survival in macrophage cultures. In fact, resveratrol anti-*Leishmania in vitro* activity has also been reported for *L. major* [41] and the authors speculated that resveratrol could exert anti-proliferative activities in promastigotes and intracellular amastigotes through the inhibition of tubulin polymerisation. Since resveratrol downregulate HIF-1 α expression [22] and it is a transcription factor that can reprogram the cell metabolism [14], we suggest that the antileishmanial effect of resveratrol could be linked to negative modulation of HIF-1 α in host macrophages. Our data showed that resveratrol did not have a significant effect on the reduction of Balb/c mice lesion, even though it is nontoxic in rodents [42]. The animal model of infection chosen was Balb/c mice, the most used *in vivo* model for experimental studies because infection with cutaneous *Leishmania* results in very aggressive and non-healing cutaneous lesions [43]. Future investigation of resveratrol treatment in other mouse strains and different *Leishmania* species would assist in a fuller understanding of how this drug effects the progression of different leishmanioses.

Echinomycin is a cyclic depsipeptide antibiotic which has been described as inhibiting HIF-1 α DNA binding and transcription activity [27,28]. It is reported to have antitumor and antibacterial activity, despite a low toxicity in *Trypanosoma brucei* and *T. rhodesiense* [44] and showed no *in vivo* antileishmanial effect (our data). In fact, administration of echinomycin induced lethality in Balb/c mice, even though previous toxicological evaluation performed in mice and dogs indicated that the clinical signs induced by the drug, such as hypoactivity, ataxia and weight loss, were reversed [34]. The reasons for this discrepancy are unclear but it is possible that *L. amazonensis* infected mice are more sensitive to the drug than uninfected mice.

Mimosine is an alkaloid that stabilizes HIF-1 α and boosts the capacity of human neutrophils to kill *Staphylococcus aureus* [30]. Our data shown that mimosine did not have a significant effect on the parasite load in *L. amazonensis* infected primary macrophages, with the exception of the *L. amazonensis* infected J774 macrophage cell line. As previously shown, the compound did not inhibit the growth of *L. donovani* promastigotes, but had effect on amastigotes within a macrophage cell line [45]. The authors suggested that the anti-*Leishmania* activity of mimosine is related to its inhibitory activity in deoxyhypusine hydroxylase, an enzyme involved in cell proliferation [45]. The differences in sensitivity between *Leishmania* species and macrophage origins to mimosine and its mechanism of action could be explored for drug development.

In conclusion, analysis of our results suggests that HIF-1 α modulation require further study to more fully determine the anti-*Leishmania* potential of HIF-1 α modulator compounds and their role in therapeutic strategies.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico (NO. 2009/10771-9) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (NO. 301052/2009-3), Brazil.

References

- [1] Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. *Nat Rev Microbiol* 2011; **9**(8): 604-615.
- [2] Okwor I, Uzonna J. Social and economic burden of human leishmaniasis. *Am J Trop Med Hyg* 2016; **94**(3): 489-493.
- [3] Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA, Handler MZ. Cutaneous and mucocutaneous leishmaniasis: clinical perspectives. *J Am Acad Dermatol* 2015; **73**(6): 897-908.
- [4] No JH. Visceral leishmaniasis: revisiting current treatments and approaches for future discoveries. *Acta Trop* 2016; **155**(2016): 113-123.
- [5] Araújo AP, Arrais-Silva WW, Giorgio S. Infection by *Leishmania amazonensis* in mice: a potential model for chronic hypoxia. *Acta Histochem* 2012; **114**(8): 797-804.
- [6] Mahnke A, Meier RJ, Schatz V, Hofmann J, Castiglione K, Schleicher U, et al. Hypoxia in *Leishmania major* skin lesions impairs the NO-dependent leishmanicidal activity of macrophages. *J Invest Dermatol* 2014; **134**(9): 2339-2346.
- [7] Araujo AP, Giorgio S. Immunohistochemical evidence of stress and inflammatory markers in mouse models of cutaneous leishmaniasis. *Arch Dermatol Res* 2015; **307**(8): 671-682.
- [8] Arrais-Silva WW, Paffaro VA Jr, Yamada AT, Giorgio S. Expression of hypoxia-inducible factor-1alpha in the cutaneous lesions of BALB/c mice infected with *Leishmania amazonensis*. *Exp Mol Pathol* 2005; **78**(1): 49-54.
- [9] Degrossoli A, Bosetto MC, Lima CB, Giorgio S. Expression of hypoxia-inducible factor 1alpha in mononuclear phagocytes infected with *Leishmania amazonensis*. *Immunol Lett* 2007; **114**(2): 119-125.
- [10] Werth N, Beerlage C, Rosenberger C, Yazdi AS, Edelmann M, Amr A, et al. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. *PLoS One* 2010; **5**(7): e11576.
- [11] Singh AK, Mukhopadhyay C, Biswas S, Singh VK, Mukhopadhyay CK. Intracellular pathogen *Leishmania donovani* activates hypoxia inducible factor-1 by dual mechanism for survival advantage within macrophage. *PLoS One* 2012; **7**(6): e38489.
- [12] Semenza GL. Targeting hypoxia-inducible factor 1 to stimulate tissue vascularization. *J Invest Med* 2016; **64**(2): 361-363.
- [13] Hubbi ME, Semenza GL. Regulation of cell proliferation by hypoxia-inducible factors. *Am J Physiol Cell Physiol* 2015; **309**(12): C775-C782.
- [14] Yang C, Jiang L, Zhang H, Shimoda LA, DeBerardinis RJ, Semenza GL. Analysis of hypoxia-induced metabolic reprogramming. *Methods Enzymol* 2014; **542**(2014): 425-455.
- [15] Tang CM, Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer. *J Gastroenterol Hepatol* 2013; **28**(3): 401-405.
- [16] Miranda E, Nordgren IK, Male AL, Lawrence CE, Hoakwie F, Cuda F, et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. *J Am Chem Soc* 2013; **135**(28): 10418-10425.
- [17] Sharma M, Machuy N, Böhme L, Karunakaran K, Mäurer AP, Meyer TF, et al. HIF-1 α is involved in mediating apoptosis resistance to *Chlamydia trachomatis*-infected cells. *Cell Microbiol* 2011; **13**(10): 1573-1585.
- [18] Darekar S, Georgiou K, Yurchenko M, Yenamandra SP, Chachami G, Simos G, et al. Epstein-Barr virus immortalization of human B-cells leads to stabilization of hypoxia-induced factor 1 alpha, congruent with the Warburg effect. *PLoS One* 2012; **7**(7): e42072.
- [19] Metheni M, Lombès A, Bouillaud F, Batteux F, Langsley G. HIF-1 α induction, proliferation and glycolysis of Theileria-infected leukocytes. *Cell Microbiol* 2015; **17**(4): 467-472.
- [20] Bhandari T, Nizet V. Hypoxia-inducible factor (HIF) as a pharmacological target for prevention and treatment of infectious diseases. *Infect Dis Ther* 2014; **3**(2): 159-174.
- [21] Jones DT, Harris AL. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. *Mol Cancer Ther* 2006; **5**(9): 2193-2202.
- [22] Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. *Mol Cancer Ther* 2005; **4**(10): 1465-1474.
- [23] Yonekura S, Itoh M, Okuhashi Y, Takahashi Y, Ono A, Nara N, et al. Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells. *Anticancer Res* 2013; **33**(8): 3099-3103.
- [24] Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. *Nat Rev Drug Discov* 2014; **13**(11): 852-869.
- [25] Mitani T, Ito Y, Harada N, Nakano Y, Inui H, Ashida H, et al. Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells. *J Nutr Sci Vitaminol (Tokyo)* 2014; **60**(2): 122-128.
- [26] Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. *Transl Res* 2015; **165**(6): 641-650.
- [27] Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. *ACS Chem Biol* 2007; **2**(8): 561-571.
- [28] Cao X, Luo T, Luo X, Tang Z. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. *Hypertens Res* 2014; **37**(9): 803-810.
- [29] Chun YS, Choi E, Kim GT, Choi H, Kim CH, Lee MJ, et al. Cadmium blocks hypoxia-inducible factor (HIF)-1-mediated response to hypoxia by stimulating the proteasome-dependent degradation of HIF-1alpha. *Eur J Biochem* 2000; **267**(13): 4198-4204.
- [30] Zinkernagel AS, Peyssonnaud C, Johnson RS, Nizet V. Pharmacologic augmentation of hypoxia-inducible factor-1alpha with mimosine boosts the bactericidal capacity of phagocytes. *J Infect Dis* 2008; **197**(2): 214-217.
- [31] Degrossoli A, Colhone MC, Arrais-Silva WW, Giorgio S. Hypoxia modulates expression of the 70-kD heat shock protein and reduces *Leishmania* infection in macrophages. *J Biomed Sci* 2004; **1**(6): 847-854.
- [32] Giorgio S, Linares E, Ischiropoulos H, Von Zuben FJ, Yamada A, Augusto O. *In vivo* formation of electron paramagnetic resonance-detectable nitric oxide and of nitrotyrosine is not impaired during murine leishmaniasis. *Infect Immun* 1998; **66**(2): 807-814.
- [33] de Mesquita Barbosa A, Dos Santos Costa S, da Rocha JR, Montanari CA, Giorgio S. Evaluation of the leishmanicidal and cytotoxic effects of inhibitors for microorganism metabolic pathway enzymes. *Biomed Pharmacother* 2015; **74**(2015): 95-100.
- [34] Foster BJ, Clagett-Carr K, Shoemaker DD, Suffness M, Plowman J, Trissel LA, et al. Echinomycin: the first bifunctional intercalating agent in clinical trials. *Invest New Drugs* 1985; **3**(4): 403-410.
- [35] Yu L, Sun ZJ, Wu SL, Pan CE. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. *World J Gastroenterol* 2003; **9**(10): 2341-2343.
- [36] Park YS, Shin WS, Kim SK. *In vitro* and *in vivo* activities of echinomycin against clinical isolates of *Staphylococcus aureus*. *J Antimicrob Chemother* 2008; **61**(1): 163-168.

- [37] Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. *Cancer Res* 2005; **65**: 9047-9055.
- [38] Radkar V, Hardej D, Lau-Cam C, Billack B. Evaluation of resveratrol and piceatannol cytotoxicity in macrophages, T cells, and skin cells. *Arh Hig Rada Toksikol* 2007; **58**(19): 293-304.
- [39] Tsuzuki T, Okada H, Cho H, Tsuji S, Nishigaki A, Yasuda K, et al. Hypoxic stress simultaneously stimulates vascular endothelial growth factor via hypoxia-inducible factor-1 α and inhibits stromal cell-derived factor-1 in human endometrial stromal cells. *Hum Reprod* 2012; **27**(2): 523-530.
- [40] IARC. Cadmium and cadmium compounds. *IARC Monogr Eval Carcinog Risks Hum* 1993; **58**(1993): 119-237.
- [41] Kedzierski L, Curtis JM, Kaminska M, Jodynis-Liebert J, Murias M. *In vitro* antileishmanial activity of resveratrol and its hydroxylated analogues against *Leishmania major* promastigotes and amastigotes. *Parasitol Res* 2007; **102**(1): 91-97.
- [42] Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. *J Nutr* 2002; **132**(2): 257-260.
- [43] Pereira BA, Alves CR. Immunological characteristics of experimental murine infection with *Leishmania (Leishmania) amazonensis*. *Vet Parasitol* 2008; **158**(4): 239-255.
- [44] Otoguro K, Ishiyama A, Namatame M, Nishihara A, Furusawa T, Masuma R, et al. Selective and potent *in vitro* antitrypanosomal activities of ten microbial metabolites. *J Antibiot (Tokyo)* 2008; **61**(10): 372-378.
- [45] Chawla B, Kumar RR, Tyagi N, Subramanian G, Srinivasan N, Park MH, et al. A unique modification of the eukaryotic initiation factor 5A shows the presence of the complete hypusine pathway in *Leishmania donovani*. *PLoS One* 2012; **7**(3): e33138.